BRIEF published on 12/22/2025 at 07:05, 3 months 7 days ago GenSight Biologics Receives Compassionate Use Authorization for GS010/LUMEVOQ® in France Gene Therapy Rare Diseases Compassionate Use LHON Treatment ANSM Approval
BRIEF published on 12/22/2025 at 07:05, 3 months 7 days ago Issuance of a compassionate access authorization for GS010/LUMEVOQ® Gene Therapy GenSight Biologics NOHL ANSM Compassionate Access
PRESS RELEASE published on 12/22/2025 at 07:00, 3 months 7 days ago Inside Information / Other news releases GenSight Biologics receives Compassionate Use Authorization in France for GS010/LUMEVOQ® gene therapy indicated for ND4-LHON treatment France GenSight Biologics GS010/LUMEVOQ® Compassionate Use Authorization ND4-LHON
BRIEF published on 11/13/2025 at 18:02, 4 months 15 days ago Heights Capital Management crosses thresholds Convertible Bonds Crossing Thresholds Shares And Voting Rights GenSight Biologics Heights Capital
BRIEF published on 10/30/2025 at 07:35, 4 months 30 days ago GenSight Biologics: Green light for compassionate treatment in the United States FDA GenSight Biologics NOHL Compassionate Access GS010/LUMEVOQ®
BRIEF published on 09/29/2025 at 23:05, 5 months 29 days ago GenSight Biologics Announces First Half 2025 Financial Results Financial Results Research And Development Treasury GenSight Biologics Early Access Programs
PRESS RELEASE published on 09/29/2025 at 23:00, 5 months 29 days ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
PRESS RELEASE published on 09/29/2025 at 21:48, 5 months 29 days ago rapport financier semestriel 2025
BRIEF published on 08/28/2025 at 20:05, 7 months ago GenSight Biologics Delays 2025 Half-Year Financial Results Announcement Financial Results Regulatory Compliance Postponement GenSight Biologics Audit Procedures
PRESS RELEASE published on 08/28/2025 at 20:00, 7 months ago Inside Information / Other news releases GenSight Biologics postpones the release of its 2025 half-year financial results to September 29, 2025, after the market closes, to ensure highest audit standards. No material issues reported. Audit Committee and Board meetings rescheduled Financial Results Transparency Postponement GenSight Biologics Audit Procedures
Published on 03/29/2026 at 12:15, 1 hour 43 minutes ago China Xlx Announces 2025 Annual Results Deepening Efforts in Reducing Costs, Enhancing Efficiency, Strengthening Competitiveness Through Differentiation and Driving Marketing Transformation
Published on 03/28/2026 at 01:00, 1 day 11 hours ago Battery X Metals Announces Confidential Submission of Amended Draft Registration Statement with the U.S. Securities and Exchange Commission in Connection with Proposed U.S. National Securities Exchange Initial Public Offering
Published on 03/28/2026 at 00:55, 1 day 12 hours ago Notification of Relevant Change to Significant Shareholder
Published on 03/27/2026 at 22:45, 1 day 14 hours ago Caledonia Mining Corporation Plc - Notification of Relevant Change to Significant Shareholder
Published on 03/28/2026 at 10:05, 1 day 3 hours ago Hisense Advances a Quiet Green Revolution in Home Entertainment
Published on 03/28/2026 at 08:56, 1 day 5 hours ago Turkiye Garanti Bankasi A.S.: Sale of Garanti Bank S.A. and our public disclosure dated 10.03.2026
Published on 03/28/2026 at 01:42, 1 day 11 hours ago EQS-Adhoc: Raiffeisen Bank International AG: Agreement on the acquisition of Garanti BBVA Group Romania
Published on 03/27/2026 at 21:58, 1 day 15 hours ago Kaufman & Broad SA: Availability of the Universal Registration Document 2025
Published on 03/27/2026 at 20:08, 1 day 16 hours ago EQS-Adhoc: CECONOMY AG: Information on the ongoing public takeover process – uncertainty regarding FDI clearance in Austria
Published on 03/27/2026 at 18:52, 1 day 18 hours ago Crédit Agricole CIB announces the publication of its 2025 Universal Registration Document
Published on 03/27/2026 at 18:40, 1 day 18 hours ago 2026 share capital increase reserved for members of the Saint-Gobain Group employee savings plan
Published on 03/27/2026 at 17:53, 1 day 19 hours ago Publication of Carrefour's 2025 Universal Registration Document
Published on 03/27/2026 at 17:45, 1 day 19 hours ago PUBLICATION OF THE UNIVERSAL REGISTRATION DOCUMENT FISCAL YEAR 2025
